Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study to Examine the Longer-Term Efficacy and Safety of Sibutramine Hydrochloride in Obese Subjects

This study has been terminated.
Sponsor:
Information provided by:
Abbott
ClinicalTrials.gov Identifier:
NCT00645255
First received: March 24, 2008
Last updated: NA
Last verified: March 2008
History: No changes posted
  Purpose

The study was designed to evaluate the long term efficacy and safety of Meridia 15 mg daily in obese subjects.


Condition Intervention Phase
Obesity
Weight Loss
Drug: placebo
Drug: sibutramine or placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Examine the Longer-Term Efficacy and Safety of Meridia (Sibutramine Hydrochloride) in Obese Subjects

Resource links provided by NLM:


Further study details as provided by Abbott:

Primary Outcome Measures:
  • Body Weight Loss [ Time Frame: Mean Change From Baseline ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Body Mass Index (BMI) [ Time Frame: Mean Change From Baseline ] [ Designated as safety issue: No ]
  • Waist/Hip Circumference [ Time Frame: Mean Change From Baseline ] [ Designated as safety issue: No ]

Enrollment: 466
Study Start Date: September 1998
Primary Completion Date: January 2003 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1
Single-blind Placebo Run-in with behavioral intervention called Health Management Resources Maintenance Program which provided weekly classes for 12 months with meal replacement
Drug: placebo
placebo one capsule daily
Placebo Comparator: 2
Double-blind Treatment with behavioral intervention called Health Management Resources Maintenance Program which provided weekly classes for 12 months with meal replacement
Drug: sibutramine or placebo
one capsule daily
Other Names:
  • ABT-911
  • Meridia
  • sibutramine

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The subject must be able to communicate meaningfully with the investigator, be legally competent, provide written informed consent, and follow a specified diet and exercise program.
  • Female subjects must be nonlactating and must either be a) at least one year postmenopausal; or b) surgically sterilized by bilateral tubal ligation, bilateral oophorectomy or hysterectomy; or c) using adequate contraceptive precautions (i.e., oral contraceptives, approved hormonal implant, intrauterine device, diaphragm with spermicide, condom with spermicide).
  • A serum pregnancy test, which must be negative, is required of all females except those who are surgically sterile or postmenopausal.
  • The subject must be at least 18 years old.
  • The subject must have a systolic blood pressure <=140 mmHg, a diastolic blood pressure<=90 mmHg, and a pulse rate <=95 beats per minute (see Section VI.I.). Treated hypertensives are allowed in the study.
  • The subject must have been enrolled in a nonpharmacologic weight loss program with documented weight loss of >=10 kg maintained for at least 6 months, have gained back <50% of their peak lost weight (while currently maintaining a weight loss of >=10 kg), and be stabilized on a weight-maintaining diet for at least 1 month prior to screening.
  • The subject's body mass index (BMI) must be >=27 kg/m2 and <=40 kg/mg2, rounded to the nearest whole unit, and must have been >=30 kg/m2 prior to initiation of the nonpharmacological weight loss program prior to screening.
  • The subject must have lived in the immediate geographic area for at least 2 years prior to screening.
  • If the subject is on chronic medication, the dose must have been constant for at least two months prior to screening.

Exclusion Criteria:

  • The subject must not have a history of anorexia nervosa.
  • The subject must not have a history of clinically significant cardiac disease, any clinically significant abnormal cardiac condition, or be known to have a clinically significantly abnormal ECG. Specifically excluded conditions include coronary artery disease, clinically significant cardiac arrhythmias, and congestive heart failure.
  • The subject must not have a history of stroke.
  • The subject must not have a history of narrow angle glaucoma.
  • The subject must not have an organic cause of obesity (e.g., untreated hypothyroidism).
  • The subject must not have a history of seizures.
  • The subject must not have severe renal or hepatic dysfunction.
  • The subject must not be using any of the following medications while taking study medication: monoamine oxidase inhibitors (e.g., furazolidone, phenelzine, procarbazine HCl, selegiline), lithium, serotonin reuptake inhibitors, opioids (e.g., dextromethorphan, meperidine, pentazocine, fentanyl), prescribed or over-the-counter weight loss agents, centrally acting appetite suppressants, tryptophan, migraine agents (e.g., sumatriptan succinate, dihydroergotamine) or any other medication that, in the opinion of the Investigator, may pose harm to the subject, obscure the effects of study medication or interfere with the process of drug absorption, distribution, metabolism, or excretion (i.e., enzyme inducers or enzyme inhibitors). The regular use of sympathomimetics (e.g. cough and cold remedies, asthma medication) is contraindicated during the study. Study medication should be discontinued for 3 days before the use of opioids. THE SUBJECT SHOULD NOT BE TAKEN OFF ANTIDEPRESSANTS IN ORDER TO BE PLACED IN THE STUDY.
  • The subject must not have a history of hypersensitivity to MERIDIA.
  • The subject must not have a history of alcohol or drug addiction.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Peter Bacher, MD, PhD, Abbott
ClinicalTrials.gov Identifier: NCT00645255     History of Changes
Other Study ID Numbers: SB118
Study First Received: March 24, 2008
Last Updated: March 24, 2008
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Weight Loss
Body Weight
Body Weight Changes
Signs and Symptoms
Sibutramine
Anti-Obesity Agents
Antidepressive Agents
Appetite Depressants
Central Nervous System Agents
Pharmacologic Actions
Psychotropic Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 27, 2014